Companies › Iksuda Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IKS014 anti-HER2 antibody-drug conjugate (MMAF payload) | ERBB2 | Phase 1 | Breast Cancer | Dec 2026 |
| IKS03 anti-CD19 antibody-drug conjugate with pyrrolobenzodiazepine cytotoxic payload | CD19 | Phase 1 | B-cell Non-Hodgkin Lymphoma | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05872295 | IKS014 | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT05365659 | IKS03 | Phase 1 | B-cell Non-Hodgkin Lymphoma | Oncology | Sep 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.